<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04335552</url>
  </required_header>
  <id_info>
    <org_study_id>PRO00105339</org_study_id>
    <nct_id>NCT04335552</nct_id>
  </id_info>
  <brief_title>Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection</brief_title>
  <official_title>Pragmatic Factorial Trial of Hydroxychloroquine, Azithromycin, or Both for Treatment of Severe SARS-CoV-2 Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a pragmatic, randomized, open-label, incomplete factorial with nested randomization&#xD;
      clinical trial evaluating the efficacy and safety of two potential treatments for&#xD;
      hospitalized patients with confirmed SARS-CoV-2 infection. Participants who are hospitalized&#xD;
      and have a positive nucleic acid amplification test for SARS-CoV-2 will undergo an initial&#xD;
      randomization in a 1:1 ratio to one of the following regimens:&#xD;
&#xD;
      Arm 1: Standard of care alone&#xD;
&#xD;
      Arm 2: Standard of care plus hydroxychloroquine&#xD;
&#xD;
      Participants who meet eligibility criteria to receive azithromycin will undergo a second&#xD;
      randomization in a 1:1 ratio to receive additional concurrent therapy. This will effectively&#xD;
      result in four treatment groups:&#xD;
&#xD;
        1. Standard of care alone&#xD;
&#xD;
        2. Standard of care plus hydroxychloroquine&#xD;
&#xD;
        3. Standard of care plus azithromycin&#xD;
&#xD;
        4. Standard of care plus hydroxychloroquine plus azithromycin&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor recruitment, strong evidence from larger trials of no therapeutic benefit&#xD;
  </why_stopped>
  <start_date type="Actual">April 17, 2020</start_date>
  <completion_date type="Actual">June 26, 2020</completion_date>
  <primary_completion_date type="Actual">June 17, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>Patients will be initially randomized to one of two arms in a 1:1 ratio: 1) Standard of care treatment or 2) Standard of care treatment plus 5 days of hydroxychloroquine. Participants who meet eligibility criteria to receive azithromycin will undergo a second randomization in a 1:1 ratio to receive additional concurrent therapy.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>World Health Organization (WHO) Ordinal Scale Measured at 14 Days After Enrollment</measure>
    <time_frame>Day 14</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died During the Index Hospitalization</measure>
    <time_frame>Index hospitalization, up to 46 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Days on Mechanical Ventilation</measure>
    <time_frame>Baseline</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients Not Receiving Mechanical Ventilation at Baseline Who Progress to Requiring Mechanical Ventilation During the Index Hospitalization</measure>
    <time_frame>Index hospitalization, up to 46 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>WHO Ordinal Scale Measured at 28 Days After Enrollment</measure>
    <time_frame>Day 28</time_frame>
    <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Length of Stay in Days for the Index Hospitalization</measure>
    <time_frame>Index hospitalization, up to 46 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With All-cause Study Medication Discontinuation</measure>
    <time_frame>Index hospitalization, up to 46 days</time_frame>
    <description>Number of participants who discontinued study medication for any reason</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Severe Adverse Events</measure>
    <time_frame>Day 14</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care plus hydroxychloroquine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care plus hydroxychloroquine for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care plus azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care plus azithromycin for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of care plus hydroxychloroquine plus azithromycin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Standard of care</intervention_name>
    <description>Standard of care</description>
    <arm_group_label>Standard of care</arm_group_label>
    <arm_group_label>Standard of care plus azithromycin</arm_group_label>
    <arm_group_label>Standard of care plus hydroxychloroquine</arm_group_label>
    <arm_group_label>Standard of care plus hydroxychloroquine plus azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
    <arm_group_label>Standard of care plus hydroxychloroquine</arm_group_label>
    <arm_group_label>Standard of care plus hydroxychloroquine plus azithromycin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
    <arm_group_label>Standard of care plus azithromycin</arm_group_label>
    <arm_group_label>Standard of care plus hydroxychloroquine plus azithromycin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Admitted to participating hospital with symptoms suggestive of COVID-19 infection OR&#xD;
             develop symptoms of COVID-19 during hospitalization&#xD;
&#xD;
          2. Subject (or legally authorized representative) can provide written informed consent&#xD;
             (in English or Spanish) affirming intention to comply with planned study procedures&#xD;
             prior to enrollment&#xD;
&#xD;
          3. Male or female adult aged 12 years or older at the time of enrollment&#xD;
&#xD;
          4. Has laboratory-confirmed SARS-CoV-2 infection determined by a validated nucleic acid&#xD;
             amplification assay (public health or commercial) in any respiratory specimen&#xD;
             collected within 14 days of randomization&#xD;
&#xD;
          5. Illness of any duration that includes&#xD;
&#xD;
               -  Radiographic evidence of pulmonary infiltrates (chest X-ray or CT scan) OR&#xD;
&#xD;
               -  Clinical documentation of lower respiratory symptoms (cough, shortness of breath,&#xD;
                  wheezing) OR&#xD;
&#xD;
               -  Any documented SpO2 ≤ 94% on room air OR&#xD;
&#xD;
               -  Any inpatient initiation or supplemental oxygen regardless of documented cause&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Participating in any other clinical trial of an experimental agent for COVID-19&#xD;
&#xD;
          2. On hydroxychloroquine at any time during hospitalization, or within 180 days of&#xD;
             hospitalization for COVID-19 regardless of indication&#xD;
&#xD;
          3. History of G6PD deficiency, cirrhosis, long QT syndrome or porphyria of any&#xD;
             classification&#xD;
&#xD;
          4. Most recent ECG prior to time of screening with QTc of ≥500 msec&#xD;
&#xD;
          5. Known hypersensitivity to hydroxychloroquine or 4-aminoquinoline derivatives&#xD;
&#xD;
          6. Death anticipated within 48 hours of enrollment&#xD;
&#xD;
          7. Inability to obtain informed consent from the patient or designated medical decision&#xD;
             maker&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jason Stout, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Regional Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke University Hospital</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Durham VA Medical Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Duke Raleigh Hospital</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>April 3, 2020</study_first_submitted>
  <study_first_submitted_qc>April 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2020</study_first_posted>
  <results_first_submitted>May 3, 2021</results_first_submitted>
  <results_first_submitted_qc>May 3, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">May 12, 2021</results_first_posted>
  <last_update_submitted>May 13, 2021</last_update_submitted>
  <last_update_submitted_qc>May 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT04335552/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 1, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT04335552/SAP_003.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>April 13, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/52/NCT04335552/ICF_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Standard of Care</title>
          <description>Standard of care: Standard of care</description>
        </group>
        <group group_id="P2">
          <title>Standard of Care Plus Hydroxychloroquine</title>
          <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
        </group>
        <group group_id="P3">
          <title>Standard of Care Plus Azithromycin</title>
          <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
        </group>
        <group group_id="P4">
          <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
          <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Standard of Care</title>
          <description>Standard of care: Standard of care</description>
        </group>
        <group group_id="B2">
          <title>Standard of Care Plus Hydroxychloroquine</title>
          <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
        </group>
        <group group_id="B3">
          <title>Standard of Care Plus Azithromycin</title>
          <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
        </group>
        <group group_id="B4">
          <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
          <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
            <count group_id="B2" value="4"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="2"/>
            <count group_id="B5" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="56.3" spread="20.5"/>
                    <measurement group_id="B2" value="59.0" spread="14.1"/>
                    <measurement group_id="B3" value="57.0" spread="4.2"/>
                    <measurement group_id="B4" value="50.3" spread="12.5"/>
                    <measurement group_id="B5" value="54.7" spread="12.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>World Health Organization (WHO) Ordinal Scale Measured at 14 Days After Enrollment</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.</description>
        <time_frame>Day 14</time_frame>
        <population>Intention to treat (includes all randomized, excludes 1 participant who withdrew prior to outcome measurement)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Plus Hydroxychloroquine</title>
            <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care Plus Azithromycin</title>
            <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
            <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
        </group_list>
        <measure>
          <title>World Health Organization (WHO) Ordinal Scale Measured at 14 Days After Enrollment</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.</description>
          <population>Intention to treat (includes all randomized, excludes 1 participant who withdrew prior to outcome measurement)</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="NA">Only one measurement</measurement>
                    <measurement group_id="O2" value="2.5" spread="3"/>
                    <measurement group_id="O3" value="5.3" spread="3.8"/>
                    <measurement group_id="O4" value="4.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died During the Index Hospitalization</title>
        <time_frame>Index hospitalization, up to 46 days</time_frame>
        <population>Intention to treat (1 participant who withdrew not included)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Plus Hydroxychloroquine</title>
            <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care Plus Azithromycin</title>
            <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
            <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died During the Index Hospitalization</title>
          <population>Intention to treat (1 participant who withdrew not included)</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Days on Mechanical Ventilation</title>
        <time_frame>Baseline</time_frame>
        <population>Intention to treat (1 participant who withdrew excluded)</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Plus Hydroxychloroquine</title>
            <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care Plus Azithromycin</title>
            <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
            <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Days on Mechanical Ventilation</title>
          <population>Intention to treat (1 participant who withdrew excluded)</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="NA">Only 1 observation</measurement>
                    <measurement group_id="O2" value="5.5" spread="11"/>
                    <measurement group_id="O3" value="8.67" spread="15"/>
                    <measurement group_id="O4" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Patients Not Receiving Mechanical Ventilation at Baseline Who Progress to Requiring Mechanical Ventilation During the Index Hospitalization</title>
        <time_frame>Index hospitalization, up to 46 days</time_frame>
        <population>Intention to treat excluding 1 participant who withdrew</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Plus Hydroxychloroquine</title>
            <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care Plus Azithromycin</title>
            <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
            <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Patients Not Receiving Mechanical Ventilation at Baseline Who Progress to Requiring Mechanical Ventilation During the Index Hospitalization</title>
          <population>Intention to treat excluding 1 participant who withdrew</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>WHO Ordinal Scale Measured at 28 Days After Enrollment</title>
        <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.</description>
        <time_frame>Day 28</time_frame>
        <population>Intention to treat excluding 1 participant who withdrew</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Plus Hydroxychloroquine</title>
            <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care Plus Azithromycin</title>
            <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
            <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
        </group_list>
        <measure>
          <title>WHO Ordinal Scale Measured at 28 Days After Enrollment</title>
          <description>The ordinal scale is an assessment of the clinical status at the first assessment of a given study day. The scale is as follows: 1) Death; 2) Hospitalized, on invasive mechanical ventilation or extracorporeal membrane oxygenation (ECMO); 3) Hospitalized, on non-invasive ventilation or high flow oxygen devices; 4) Hospitalized, requiring supplemental oxygen; 5) Hospitalized, not requiring supplemental oxygen - requiring ongoing medical care (COVID-19 related or otherwise); 6) Hospitalized, not requiring supplemental oxygen - no longer requires ongoing medical care; 7) Not hospitalized, limitation on activities and/or requiring home oxygen; 8) Not hospitalized, no limitations on activities.</description>
          <population>Intention to treat excluding 1 participant who withdrew</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="NA">Only 1 participant</measurement>
                    <measurement group_id="O2" value="2.8" spread="3.5"/>
                    <measurement group_id="O3" value="5.3" spread="3.8"/>
                    <measurement group_id="O4" value="4.5" spread="5.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Length of Stay in Days for the Index Hospitalization</title>
        <time_frame>Index hospitalization, up to 46 days</time_frame>
        <population>Intention to treat excluding 1 participant who withdrew</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Plus Hydroxychloroquine</title>
            <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care Plus Azithromycin</title>
            <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
            <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Length of Stay in Days for the Index Hospitalization</title>
          <population>Intention to treat excluding 1 participant who withdrew</population>
          <units>days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6" spread="NA">Only 1 participant</measurement>
                    <measurement group_id="O2" value="9" spread="11"/>
                    <measurement group_id="O3" value="14.7" spread="14.6"/>
                    <measurement group_id="O4" value="2.5" spread="0.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With All-cause Study Medication Discontinuation</title>
        <description>Number of participants who discontinued study medication for any reason</description>
        <time_frame>Index hospitalization, up to 46 days</time_frame>
        <population>Intention to treat excluding 1 participant who withdrew</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Plus Hydroxychloroquine</title>
            <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care Plus Azithromycin</title>
            <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
            <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With All-cause Study Medication Discontinuation</title>
          <description>Number of participants who discontinued study medication for any reason</description>
          <population>Intention to treat excluding 1 participant who withdrew</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Severe Adverse Events</title>
        <time_frame>Day 14</time_frame>
        <population>Intention to treat excluding 1 participant who withdrew</population>
        <group_list>
          <group group_id="O1">
            <title>Standard of Care</title>
            <description>Standard of care: Standard of care</description>
          </group>
          <group group_id="O2">
            <title>Standard of Care Plus Hydroxychloroquine</title>
            <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
          </group>
          <group group_id="O3">
            <title>Standard of Care Plus Azithromycin</title>
            <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
          <group group_id="O4">
            <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
            <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Severe Adverse Events</title>
          <population>Intention to treat excluding 1 participant who withdrew</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
                <count group_id="O2" value="4"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                    <measurement group_id="O3" value="1"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Standard of Care</title>
          <description>Standard of care: Standard of care</description>
        </group>
        <group group_id="E2">
          <title>Standard of Care Plus Hydroxychloroquine</title>
          <description>Standard of care plus hydroxychloroquine for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5</description>
        </group>
        <group group_id="E3">
          <title>Standard of Care Plus Azithromycin</title>
          <description>Standard of care plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
        </group>
        <group group_id="E4">
          <title>Standard of Care Plus Hydroxychloroquine Plus Azithromycin</title>
          <description>Standard of care plus hydroxychloroquine plus azithromycin for 5 days&#xD;
Standard of care: Standard of care&#xD;
Hydroxychloroquine: Hydroxychloroquine will be administered orally or via feeding tube at a dosage of 800 mg on day 1, followed by 600 mg daily on days 2-5&#xD;
Azithromycin: Azithromycin will be administered orally or via feeding tube at a dosage of 500 mg on day 1, followed by 250 mg daily on days 2-5</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="2"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute renal failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <description>Acute respiratory failure requiring intubation</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="4"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="4"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="2"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jason Stout, MD, MHS</name_or_title>
      <organization>Duke University</organization>
      <phone>919-668-0826</phone>
      <email>jason.stout@dm.duke.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

